Literature DB >> 27012491

Amyloid biomarkers: pushing the limits of early detection.

Gil D Rabinovici1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27012491      PMCID： PMC5006231          DOI： 10.1093/brain/aww025

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  10 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 2.  Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions.

Authors:  Sandrine Andrieu; Nicola Coley; Simon Lovestone; Paul S Aisen; Bruno Vellas
Journal:  Lancet Neurol       Date:  2015-07-23       Impact factor: 44.182

Review 3.  Amyloid biomarkers in Alzheimer's disease.

Authors:  Kaj Blennow; Niklas Mattsson; Michael Schöll; Oskar Hansson; Henrik Zetterberg
Journal:  Trends Pharmacol Sci       Date:  2015-04-01       Impact factor: 14.819

4.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings
Journal:  Lancet Neurol       Date:  2014-06       Impact factor: 44.182

5.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

6.  Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

Authors:  Niklas Mattsson; Philip S Insel; Michael Donohue; Susan Landau; William J Jagust; Leslie M Shaw; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow; Michael W Weiner
Journal:  Brain       Date:  2014-12-24       Impact factor: 13.501

7.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

Authors:  Nigel J Cairns; Milos D Ikonomovic; Tammie Benzinger; Martha Storandt; Anne M Fagan; Aarti R Shah; Lisa Taylor Reinwald; Deborah Carter; Angela Felton; David M Holtzman; Mark A Mintun; William E Klunk; John C Morris
Journal:  Arch Neurol       Date:  2009-12

Review 8.  Is amyloid-β harmful to the brain? Insights from human imaging studies.

Authors:  William Jagust
Journal:  Brain       Date:  2015-11-27       Impact factor: 13.501

9.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

10.  Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.

Authors:  Sebastian Palmqvist; Niklas Mattsson; Oskar Hansson
Journal:  Brain       Date:  2016-03-02       Impact factor: 13.501
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.